Biotech entity
Every one of those 1 sits in a single category, pharma. ACTION3 is most often covered alongside DMX-200, which appears in 1 of these 1 story. Each carries 4 original sources on average. We currently track 1 Biotech story that mention ACTION3, all published on July 12, 2026.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. ACTION3 is most often covered alongside DMX-200, which appears in 1 of these 1 story. Each carries 4 original sources on average. We currently track 1 Biotech story that mention ACTION3, all published on July 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ACTION3. Shared-story counts are live from our verified record — not editorial picks.
Exclusive License Agreement
Dimerix announces licensing deal with Everest Medicines for Asian commercialization.
Eighth DSMB Safety Review
Independent committee finds no safety concerns in ongoing trial.
Statistical Power Confirmation
External blinded review confirms the trial retains over 90% statistical power for the primary endpoint.
Positive Interim Results
Dimerix reports DMX-200 performing better than placebo in reducing proteinuria in the ACTION3 adult cohort.
Biotech Dimerix secures a regional licensing deal with Everest Medicines, retaining Western rights for its Phase 3 FSGS candidate. Trial remains on track with strong interim efficacy and clean safety, plus a high probability of success.
Source: malaysiasun.com · asiabulletin.com
ACTION3 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
